Cargando…
Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
BACKGROUND AND OBJECTIVES: Dalbavancin is a novel, once-weekly glycopeptide antibiotic approved for treatment of acute bacterial skin infections. Given the importance of understanding any pharmacokinetic variability across different patient populations, a double-blind, placebo-controlled study was c...
Autores principales: | Scoble, Patrick J., Owens, Robert C., Puttagunta, Sailaja, Yen, Mark, Dunne, Michael W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4659844/ https://www.ncbi.nlm.nih.gov/pubmed/26458939 http://dx.doi.org/10.1007/s40261-015-0340-4 |
Ejemplares similares
-
267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014) -
Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
por: Rappo, Urania, et al.
Publicado: (2019) -
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
por: Dunne, Michael W, et al.
Publicado: (2015) -
Interchangeability of Two 500 Mg Amoxicillin Capsules with One 1000 Mg Amoxicillin Tablet After a Single Oral Administration
por: Zaid, A. N., et al.
Publicado: (2010) -
Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)